文献简介

出版社:Canadian Dermatology Association

作  者:Amrinder J. Kanwar, Rahul Mahajan, and Davinder Parsad

编  号:10.2310/7750.2013.12053

关键字:

年  份:2013   点击量:1132

文献摘要

Background:

 The course of vitiligo is unpredictable. If the disease is spreading rapidly, the progression can be controlled with the use of systemic steroids daily or in pulsed form. The present study was planned to assess the efficacy of low-dose dexamethasone oral mini-pulse therapy in progressive unstable vitiligo.
研究背景:
   
白癜风的病程难以预知。如果病情迅速蔓延,可以通过每日系统性使用类固醇或冲击疗法控制病情发展。本研究旨在评估口服低剂量地塞米松微冲击疗法对进行性不稳定性白癜风的疗效。

Materials and Methods:
     In this retrospective study, the case records of patients with vitiligo during the period from January 2006 to December 2010 were studied. Patients who had progressive unstable disease were included. These patients were administered oral dexamethasone 2.5 mg per day on 2 consecutive days after breakfast in a week. The patients were asked to come for regular follow-up to assess the arrest of disease activity, relapse of disease activity, and adverse effects.
材料和方法:
    在这项回顾性研究中,我们研究了
20061月至201012月期间白癜风患者的病历。研究对象为进行性不稳定性白癜风的患者。这些患者一周内连续2天每日早餐后口服地塞米松2.5mg。要求患者做定期随访,以评估疾病的活动性、复发,以及不良反应。
Results:
    A total of 444 patients were analyzed. In 408 (91.8%) patients, arrest of disease  activity was achieved at a mean duration of 13.2 ± 3.1 weeks. In addition, some repigmentation of the lesions was seen in all patients after a mean of 16.1 ± 5.9 weeks. During the follow-up, 50 of 408 (12.25%) patients experienced one or two episodes of relapse in disease activity, which were treated with reinstitution of low-dose dexamethasone oral mini-pulse therapy. The mean disease-free survival (DFS) until the first relapse was 55.7 ± 26.7 weeks, and the mean DFS until the second relapse was 43.8 ± 7.2 weeks. Adverse reactions such as weight gain, lethargy, and acneiform eruptions were observed in 41 (9.2%) patients.
研究结果:
    总共分析了444名患者,有408例(占91.8%)患者的疾病活动性得于平均13.2±3.1周得到控制。另外,所有的患者于平均16.1±5.9周后有一些皮损部位色素再生。随访期间, 408名患者中有50名(12.25%)疾病活动性反复12次,通过重新口服低剂量地塞米松微冲击疗法的进行了治疗。平均无病生存期(DFS)【无病生存(DFS):是指从随机化开始至疾病复发或由于疾病进展导致患者死亡的时间】到第一次疾病复发为55.7±26.7个星期,平均DFS到第二次复发为43.8±7.2周。41例(占9.2%)患者出现不良反应,如体重增加、嗜睡、痤疮样皮疹。
Conclusion:
    Low-dose oral mini-pulsed examethasone therapy is a good option for arresting progressive unstable vitiligo with minimal adverse effects.

研究结论:

口服低剂量地塞米松微冲击疗法对于控制进行性不稳定性白癜风是一个很好的选择,并且不良反应较低。